Linvoseltamab-Gcpt Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 5 mg/2.5 mL
Reference Brands: Lynozyfic (USA/EU)
Category: Oncology Cancer Care
Linvoseltamab‑gcpt is a bispecific T‑cell engager antibody that binds to CD3 on T‑cells and BCMA on malignant plasma (myeloma) cells. This facilitates T‑cell activation and directs T cells to kill multiple myeloma cells. Lynozyfic is indicated for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (including a proteasome inhibitor, im‑modulatory agent and an anti‑CD38 antibody). Linvoseltamab-gcpt is available in Injection and strengths such as 5 mg/2.5 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Linvoseltamab-gcpt is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Linvoseltamab-gcpt can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Linvoseltamab‑gcpt is used to treat adults with relapsed or refractory multiple myeloma, particularly those who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody.
It is a bispecific T‑cell engaging antibody produced in cell culture, designed to bind CD3 on T‑cells and B‑cell maturation antigen (BCMA) on multiple myeloma cells, directing T‑cells to kill the cancer cells.
The trade name is Lynozyfic.
It is manufactured by Regeneron Pharmaceuticals, Inc.
The generic name is linvoseltamab‑gcpt.
The brand name is Lynozyfic.
It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cell culture and formulated as a sterile intravenous drug.
Related Products
Motixafortide Acetate
Strength:
1 mg/mL
Form: Injection
Reference Brands: Aphexda (USA)
View Details
Momelotinib
Strength:
100 mg, 150 mg, 200 mg
Form: Tablets
Reference Brands: Ojjaara (USA)
View Details
Nirogacestat
Strength:
50 mg
Form: Tablets
Reference Brands: Generic formulations marketed under different names
View DetailsQuick Response Guaranteed | Verified Suppliers
